Ulcerative Colitis Induced by Secukinumab in the Treatment of Ankylosing Spondylitis
Fuente:
Redalyc
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Asociación Colombiana de Gastroenterologia
2023
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1876459725668745216 |
|---|---|
| author | Ileana Rocío Bautista-Parada |
| author_facet | Ileana Rocío Bautista-Parada |
| contents | Ulcerative Colitis Induced by Secukinumab in the Treatment of Ankylosing Spondylitis Ileana Rocío Bautista-Parada Fabián Eduardo Puentes-Manosalva Medicina Secukinumab ulcerative colitis ankylosing spondylitis Interleukin 17 (IL-17) inhibitors are approved for treating psoriasis, psoriatic arthropathy, and ankylosing spondylitis. IL-17 is involved in the pathogenesis of inflammatory bowel disease (IBD); however, paradoxical events have been reported using selective IL-17 inhibitors such as secukinumab, whose pathophysiological mechanisms have not been fully clarified. Although the incidence of IBD in this group of patients is low, the risk could be reduced by carefully assessing risk factors such as family history, gastrointestinal symptoms, and fecal calprotectin before starting treatment. 2023 otro 0120-9957 https://www.redalyc.org/articulo.oa?id=337779447011 https://www.redalyc.org/journal/3377/337779447011/ https://www.redalyc.org/journal/3377/337779447011/html/ https://www.redalyc.org/journal/3377/337779447011/337779447011.epub https://www.redalyc.org/journal/3377/337779447011/movil 10.22516/25007440.884 en http://www.redalyc.org/revista.oa?id=3377 Revista Colombiana de Gastroenterología application/pdf Asociación Colombiana de Gastroenterologia Revista Colombiana de Gastroenterología (Colombia) Num.1 Vol.38 |
| format | Artículo científico |
| id | redalyc_337779447011 |
| institution | Redalyc |
| language | en |
| publishDate | 2023 |
| publisher | Asociación Colombiana de Gastroenterologia |
| spellingShingle | Ulcerative Colitis Induced by Secukinumab in the Treatment of Ankylosing Spondylitis Ileana Rocío Bautista-Parada Medicina Secukinumab ulcerative colitis ankylosing spondylitis Ulcerative Colitis Induced by Secukinumab in the Treatment of Ankylosing Spondylitis Ileana Rocío Bautista-Parada Fabián Eduardo Puentes-Manosalva Medicina Secukinumab ulcerative colitis ankylosing spondylitis Interleukin 17 (IL-17) inhibitors are approved for treating psoriasis, psoriatic arthropathy, and ankylosing spondylitis. IL-17 is involved in the pathogenesis of inflammatory bowel disease (IBD); however, paradoxical events have been reported using selective IL-17 inhibitors such as secukinumab, whose pathophysiological mechanisms have not been fully clarified. Although the incidence of IBD in this group of patients is low, the risk could be reduced by carefully assessing risk factors such as family history, gastrointestinal symptoms, and fecal calprotectin before starting treatment. 2023 otro 0120-9957 https://www.redalyc.org/articulo.oa?id=337779447011 https://www.redalyc.org/journal/3377/337779447011/ https://www.redalyc.org/journal/3377/337779447011/html/ https://www.redalyc.org/journal/3377/337779447011/337779447011.epub https://www.redalyc.org/journal/3377/337779447011/movil 10.22516/25007440.884 en http://www.redalyc.org/revista.oa?id=3377 Revista Colombiana de Gastroenterología application/pdf Asociación Colombiana de Gastroenterologia Revista Colombiana de Gastroenterología (Colombia) Num.1 Vol.38 |
| title | Ulcerative Colitis Induced by Secukinumab in the Treatment of Ankylosing Spondylitis |
| topic | Medicina Secukinumab ulcerative colitis ankylosing spondylitis |
| url | https://www.redalyc.org/articulo.oa?id=337779447011 https://www.redalyc.org/journal/3377/337779447011/ https://www.redalyc.org/journal/3377/337779447011/html/ https://www.redalyc.org/journal/3377/337779447011/337779447011.epub https://www.redalyc.org/journal/3377/337779447011/movil |